PT  - JOURNAL ARTICLE
AU  - Mizumoto, Kenji
AU  - Kagaya, Katsushi
AU  - Chowell, Gerardo
TI  - Early epidemiological assessment of the transmission potential and virulence of coronavirus disease 2019 (COVID-19) in Wuhan City: China, January-February, 2020
AID  - 10.1101/2020.02.12.20022434
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.02.12.20022434
4099  - http://medrxiv.org/content/early/2020/03/13/2020.02.12.20022434.short
4100  - http://medrxiv.org/content/early/2020/03/13/2020.02.12.20022434.full
AB  - Background Since the first cluster of cases was identified in Wuhan City, China, in December, 2019, coronavirus disease 2019 (COVID-19) has rapidly spread across China, causing multiple introductions in 109 countries/territories/areas as of March 10th. Despite the scarcity of publicly available data, scientists around the world have made strides in estimating the magnitude of the epidemic, the basic reproduction number, and transmission patterns. Recently more evidence suggests that a substantial fraction of the infected individuals with the novel coronavirus show little if any symptoms, which suggest the need to reassess the transmission potential of this emerging disease. In this study, we derive estimates of the transmissibility and virulence of COVID-19 in Wuhan City, China, by reconstructing the underlying transmission dynamics using multiple data sources.Methods We employ statistical methods and publicly available epidemiological datasets to jointly derive estimates of transmissibility and severity associated with the novel coronavirus. For this purpose, the daily series of laboratory–confirmed COVID-19 cases and deaths in Wuhan City and epidemiological data of Japanese evacuees from Wuhan City on board government–chartered flights were integrated into our analysis.Results Our posterior estimates of basic reproduction number (R) in Wuhan City, China in 2019–2020 reached values as high as 5.20 (95%CrI: 5.04–5.47) and the enhanced public health intervention after January 23rd in 2020 was associated with a declined R at 0.58 (95%CrI: 0.51–0.64), with the total number of infections (i.e. cumulative infections) estimated at 1905526 (95%CrI: 1350283– 2655936) in Wuhan City, raising the proportion of infected individuals to 19.1% (95%CrI: 13.5–26.6%). We also found that most recent crude infection fatality ratio (IFR) and time–delay adjusted IFR is estimated to be 0.04% (95% CrI: 0.03%–0.06%) and 0.12% (95%CrI: 0.08–0.17%), which is several orders of magnitude smaller than the crude CFR estimated at 4.19%Conclusions We have estimated key epidemiological parameters of the transmissibility and virulence of COVID-19 in Wuhan, China during January-February, 2020 using an ecological modelling approach. The power of our approach lies in the ability to infer epidemiological parameters with quantified uncertainty from partial observations collected by surveillance systems.Competing Interest StatementThe authors have declared no competing interest.Funding StatementKM acknowledges support from the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 18K17368 and from the Leading Initiative for Excellent Young Researchers from the Ministry of Education, Culture, Sport, Science & Technology of Japan. KK acknowledges support from the JSPS KAKENHI Grant Number 18K19336 and 19H05330. GC acknowledges support from NSF grant 1414374 as part of the joint NSF–NIH–USDA Ecology and Evolution of Infectious Diseases program.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe present study relies on published data and access information to essential components of the data are available from the corresponding author.CFRCase fatality ratioIFRInfection Fatality ratioSARSSevere Acute Respiratory SyndromeMERSMiddle East Respiratory Syndrome